phs001629
A secondary mutation in BRAF confers resistance to RAF inhibition in a BRAF V600E-mutant brain tumor
A single adolescent patient with a BRAF V600E mutated brain tumor was treated with dabrafenib and had a complete response, followed by progression. The pre-treatment and post-progression tumors were both sequenced in order to identify potential drivers of resistance.